Bausch + Lomb Corp's stock has shown modest upward movement this week, reflecting ongoing developments in its eye health therapies.
Bausch + Lomb Corp (BLCO.TO) has experienced a slight increase in its stock price this week, closing at C$24.10, which is a 1.18% rise from the previous day. The company's recent advancements in eye health therapies and its positioning in the healthcare sector are drawing attention from investors.
Advertisement
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.72B
52W high
$25.70
52W low
$19.36
1W change
+2.39%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO · as of Oct 5, 2026
Wall Street analysts forecast BLCO stock price to rise 5.6% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.78
+5.6% Upside
Previously C$25.77 on Oct 2, 2026
Current Price
C$24.41
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
21.6%
Annualized
90-Day Vol
27.2%
Annualized
Trend (90d)
+12.0%
Annualized drift
90d Mean
C$25.48
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$24.76 | C$22.98 – C$26.68 |
| 60 trading days | C$25.12 | C$22.61 – C$27.91 |
| 90 trading days | C$25.48 | C$22.39 – C$29.00 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the company's recent advancements in eye health therapies while being mindful of its current financial metrics, including a negative profit margin and return on equity.
Bausch + Lomb's stock is up 0.46% this week, closing at C$24.10.
With a market cap of approximately C$8.5 billion, Bausch + Lomb's stock remains within 75% of its 52-week range, indicating some volatility but also potential for growth.
Bull case
Bausch + Lomb is focused on developing innovative eye health therapies, which could position the company well in a growing market. This focus may lead to increased revenue and a higher market capitalization over time.
Bear case
However, the company is currently facing challenges, including a negative profit margin and return on equity. These issues may raise concerns about its financial stability and growth potential.
Recent Price Action
Advertisement
Bausch + Lomb Corp's stock closed at C$24.10, reflecting a 1.18% increase from the previous trading day. Over the past week, the stock has gained 0.46%, and over the last month, it has risen by 1.86%. Year-to-date, the stock is up 5.75%, indicating a generally positive trajectory despite some fluctuations.
Company News
Recently, Bausch + Lomb has been making headlines for advancing two first-in-class eye health therapies. The company is also planning to move a dual-action eye drop targeting evaporative and inflammatory dry eye disease to Phase 3 trials. These developments are crucial as they may enhance the company’s product offerings and market presence in the eye care sector.
Technical Picture
From a technical standpoint, Bausch + Lomb's stock is currently trading above its 50-day moving average of C$23.11 and its 200-day moving average of C$22.80, indicating a short-term bullish trend. The stock's 52-week range is between C$19.36 and C$25.70, suggesting that it is currently trading at approximately 75% of its range. With a beta of 0.55, the stock exhibits lower volatility compared to the market, which may appeal to risk-averse investors.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
